The company has secured United States Food and Drugs Administration (USFDA) approval for five of its drugs, which it plans to start exporting during the current financial year. These are generic drugs for cardiac ailments.

Lupin already makes the branded version of these drugs for the domestic market. With approval of the generic medicines, Lupin is specifically targeting the US market.

So far, the company was carrying out research and development work at the Mihan plant. Now, commercial production can begin as the approvals from USFDA have been secured. The company has put up 20 drugs for approval out of which it has got USFDA green signal for five. The process continues for the rest. Majority of the drugs relate to cardiac ailments.

The 25 acre plant in Mihan has dedicated 15 acres for tablets and 9 acres for injectables. The injectables for cancer treatment are part of the company’s future plans. Under development at present, the injectables are expected to be put up for approval after two years.